Ocular Therapeutix to present additional SOL-1 Phase 3 AXPAXLI data at April conferences

Ocular Therapeutix Inc +10.45% Pre

Ocular Therapeutix Inc

OCUL

9.30

9.20

+10.45%

-1.06% Pre
  • Ocular Therapeutix will present additional SOL-1 Phase 3 superiority trial data and analyses for AXPAXLI (OTX-TKI) in wet age-related macular degeneration at Vit-Buckle Society annual meeting on April 9-11, 2026 in Las Vegas.
  • Company will also participate in Congreso Nacional de Oftalmologia (CNO) 2026 on April 15-17, 2026 in Buenos Aires, with presentations focused on tyrosine kinase inhibitors, diabetic retinal disease, and neovascular AMD.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief on April 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.